Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

21 Jun 2016

Abstract excerpt

PURPOSE: To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and significance of PD-L1 protein expression with a validated antibody and CD274 gene alternation in a large cohort of triple negative breast cancer (TNBC) and correlated with clinicopathological data and patients overall survival. METHODS: Immunohistochemistry and in situ mRNA hybridization was used...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27390646
DOI: 10.1186/s40064-016-2513-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarkerPMID 27390646Read ↗

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohortSemantic proximity Read ↗

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohortSemantic proximity Read ↗

Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast CancerSemantic proximity Read ↗

Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant settingSemantic proximity Read ↗

PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancerSemantic proximity Read ↗

Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancerSemantic proximity Read ↗

Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine modelSemantic proximity Read ↗

Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome DataSemantic proximity Read ↗

Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancerSemantic proximity Read ↗

Predictive Role of Peripheral Blood Lymphocyte And Cytokine Phenotypes in Patients with Operable Breast Cancer And Neoadjuvant Therapy: A Preliminary StudySemantic proximity Read ↗

High CTLA-4 gene expression is an independent good prognosis factor in breast cancer patients, especially in the HER2-enriched subtypeSemantic proximity Read ↗

Gene code CD274/PD-L1 : from molecular basis toward cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.